Ei­sai plots new drug ap­pli­ca­tions in US, Eu­rope and Chi­na af­ter Lenvi­ma scores in head-to-head liv­er can­cer study

Ei­sai says that its can­cer drug Lenvi­ma (lenva­tinib) hit the pri­ma­ry end­point in a Phase III study for first-line use against liv­er can­cer, prov­ing non-in­fe­ri­or to Nex­avar. That suc­cess, the com­pa­ny adds, will set up reg­u­la­to­ry fil­ings in the US, Eu­rope and Asia.

Al­ready ap­proved for kid­ney can­cer, Tokyo-based Ei­sai says their drug scored on the over­all sur­vival rate, test­ing it in a study with 954 pa­tients. And in­ves­ti­ga­tors added that the drug al­so hit on a slate of sec­ondary end­points in­clud­ing progress-free sur­vival, time to pro­gres­sion and the ob­jec­tive re­sponse rate.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER